The size of the problem
The actual size of the global tobacco problem is increasing at a startling rate. There are several reasons for this. One is the development of new markets and new generations of smokers, not by accident but by design for which the industry is responsible. The second is the predictable effect of long duration smoking in such countries as China and central and eastern Europe where the smoking of past decades is still to wreak its full havoc. The third is the maturation of the tobacco epidemic among women.
The most important determinant of lung cancer risk is the duration of smoking: long-term smokers have a 20-30-fold increased risk compared to non-smokers [21] . Risk varies also with other aspects of daily exposure including number of cigarettes smoked, depth of inhalation and smoke composition (tar components and nicotine). Lung cancer is the major tobacco related site and is the leading cause of cancer death in men in almost all developed countries. Annual incidence rates are between 80-100 per 100,000 in the highest incidence rate groups such as Afro-Americans [22] and rates exceeding 200 per 100,000 have been recorded among middle aged men in cities of central and eastern Europe [23] . Lung cancer being frequently and rapidly fatal, mortality rates are high and, consequently, the social costs are high. Smoking among women in some developed countries has had the same effect as in men, with lung cancer now exceeding breast cancer as the most common cause of cancer death in the US, Canada, Denmark, Scotland and in many other countries the gap between the two is decreasing rapidly. Indeed, in Glasgow in Scotland, the incidence of lung cancer in women now exceeds the incidence of breast cancer [24] .
Cigarette smoking kills half of all those who adopt and persist with this addictive habit with half of these deaths occurring in middle age and each losing over 20 years of non smokers life expectancy [17] . Tobacco smoking kills effectively in twenty-four different ways [17] . It can be estimated that, whereas it will cause 3,000,000 deaths per annum in the last half of this decade, by 2025 it will cause 10,000,000 deaths annually [18] .
This global epidemic can only be ameliorated, and only to a limited degree, by controlling the tobacco industry's commitment to market expansion and by regulating the cigarette itself. Policies to reduce sales and consumption of cigarettes have been established for decades [25] . They include abolition of tobacco advertising both direct and indirect, increased taxation, education programs, smoking cessation programs and limits on tar and nicotine yields.
Public Health policy has not hitherto included detailed control of tobacco or the additives which go into modern cigarettes. This is remarkable. It now seems only a matter of time before these items are regulated.
The regulation of tobacco smoke
Regulation of the content and yield of cigarettes will be complex. The complexity arises only partly from the mixture of compounds in cigarette smoke. Difficulties arise from the need to consider and regulate nicotine in the context of addiction en masse, and as a second issue, the need to reduce the disease causing potential of the mixture.
Regulation may reasonably be expected to render the cigarette less disastrous, it cannot be expected that modifying the products of combustion of tobacco can ever produce an even moderately safe cigarette.
Historically the tobacco industry in the US has largely escaped regulation, although pressure has been applied to what is a global industry via voluntary agreements in the UK and Canada requiring reduced yields of tar, nicotine and carbon monoxide. The European Community (EC) currently mandates an upper limit for tar of 12 mg [26] . In the US, however, the industry has been free to make its own decisions, and the results are apparent both in the marketplace and in the mortality rates among smokers. Although sales weighted tar is below 12 mg [27] the range of tar is up to 27 mg [28, 29] . However, the means of achieving reduced yields of tar, nicotine and carbon monoxide to the Federal Trade Commission (FTC) machine have not necessarily delivered lower yields of carcinogens to the smokers. The FTC machine produces measures of tar and nicotine abstracted from a cigarette using a machine taking fixed 'puffs' and fixed intervals of time. Since there are fundamental differences between smokers in the frequency and strength of puffs, this technology can only provide an index. Furthermore, the addition of ventilated filters can further lead to reducing observed tar and nicotine levels. While the FTC method is quantitatively misleading, there have been qualitative changes too. Hoffmann and Hoffmann [28] have shown that the smoke of a leading US non filter brand shows a decrease in benzo(a)pyrene (BaP) by 60% between the mid sixties and late seventies, while the tobacco specific carcinogen 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) has increased by 50% between the late seventies and the nineties.
One must pause to ask whether, if cigarettes were regulated like pharmaceuticals or foodstuffs, any regulator would have condoned such an increase in a known carcinogen.
The early concept that simply reducing tar and nicotine would reduce cancer risk was well founded on epidemiological studies, which showed a reduction in lung cancer risk, but not cardiovascular disease, of between twenty and fifty percent in association with the move to filter cigarettes which occurred over the fifties and sixties [30] [31] [32] [33] [34] [35] [36] . It was therefore logical that public health authorities should press for further reductions. However the reductions which appeared in the yields as measured by the FTC system do not reflect, in a quantitative way, what passes into the lungs of smokers. That more intensive ('compensatory') smoking patterns are seen in smokers was demonstrated by Russell in 1980 and many others [37] [38] [39] [40] [41] [42] [43] .
In the absence of systematic on-going analysis of what has been going into smokers lungs, we are left with biological outcomes as an index of what has been happening. There are three potentially important observations in this regard.
First of all, it is very difficult to imagine that the large fall in the tar content of cigarettes sold in the UK over the last fifty years [44] has not directly influenced the lung cancer death rate which has been falling for two decades in men in that country.
Secondly, and somewhat paradoxically, mortality from lung cancer in men increased between the first (CPS-I) and second (CPS-II) Cancer Prevention Studies of the American Cancer Society [45, 46] : these studies recruited men from birth cohorts approximately 30 years apart. At first glance, the decrease in mortality promised by the yield reductions of the 1950s and 1960s has not been substantiated over the 1970s and 1980s. However, this may be too simple an interpretation.
Information of the number of cigarettes smoked at time of enrolment to both studies may not mirror the lifelong patterns of smoking that cause lung cancer [47] : data on smoking in early life, which critically determines duration of smoking, are sparse in both studies. Cigarette consumption during adolescence and early adulthood was probably heavier among smokers in CPS-II for several reasons. Manufactured cigarettes were more readily available in the 1940s and 1950s than in the 1930s and 1940s, eras when smoking was likely to be initiated in the CPS-II and CPS-I cohort, respectively.
Birth cohort analyses show that the prevalence of smoking among white men increased with each successive birth cohort born from 1900-1929 and decreased thereafter [48] . Age-specific lung cancer death rates have decreased in those born after 1930 [49, 50] .
The increases in lung cancer death rates from CPS-I to CPS-II probably reflect unmeasured heavier smoking among CPS-II during the 1940s and 1950s as well as the measured increase in daily consumption and duration of smoking. In addition, CPS-II may include a more addicted 'hard-core' smokers, who find it virtually impossible to quit smoking, and CPS-II smokers, partly to compensate for lower nicotine content of modern cigarettes, may inhale more deeply, take more puffs per cigarette and retain smoke larger in the lungs than did smokers in the past. The impact of lower tar and nicotine cigarettes is difficult to elucidate with all these other changes in effect.
Thirdly, and what is clear, is that there has been a real swing towards higher rates of adenocarcinoma of the lung both in the US and elsewhere [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] which is consistent with the hypothesis that qualitative changes in cigarette smoke have led to a change in the observed pattern of lung cancer but not to a substantial decrease in mortality.
Clearly cigarettes are different but still seriously harmful after decades of self-regulation.
The carcinogenic component
It is possible to conceive a system for regulation of carcinogens and other toxins in cigarette smoke which could follow the precedents set by the regulation of the automobile industry. The Environmental Protection Authorities around the world did not allow the automobile industry to set standards. Dialogue occurred and standards were set, initially as targets and ultimately as standards. The result has been a progressive reduction in air pollution achieved with the active assistance of the automobile industry's research facilities, and can be seen as a public health triumph. Regulation has been common-sense. Lead could only be reduced by removing it from petrol. Other emissions depended on engine design and the manufacturers were set targets and standards which they could, and have, met.
With regard to the many components which make up tar, we should look to the EPA model with targets to be followed by standards. Analysis of the top twenty brands for the major toxins /carcinogens would show the upper and lower limits of the present market. As a starting point it would show what is practical now. Setting target levels in the middle ranges would be a beginning and research over time would show which targets could be met, and converted to industry standards, and which could not [61] . This may mean telling the manufacturers of specific brands that they must, over time, bring levels of, say, polyaromatic hydrocarbons or nitrosamines, down to those of other brands on the market, or vice versa. It may also require sharing of manufacturing secrets.
This approach is compatible with that described as the 'Selective Reduction of specific toxic constituents' pursued by RJ Reynolds in the development of their recent 'heated tobacco' cigarette (Eclipse/Premier) [62] . This product delivers lower levels of some 37 'biologically active' compounds thought by the industry to be worthy of testing. Review of the material presented in favour of 'Eclipse' establishes that the industry has the skills and knowledge to work in this way, although only a few outside the industry would have the detailed knowledge possessed by it.
Such regulation is practical and in accord with established drug control and air quality control precedents. Drugs with carcinogenic activity are already regulated. In this case the whole process must be seen for what it is, a huge human experiment. The authorities must have the right to allow what seems to be best practice on the basis of existing knowledge. They must also be immune from litigation over their efforts. Ongoing monitoring by animal tests, laboratory tests and some cohort studies will be needed. The changes required will probably be more often based on what comes out of the cigarette than what goes into it. The manufacturers will have to use their substantial research skills under regulatory scrutiny instead of in secret. This latter point may require some legal protection which will allow the industry to tell what it knows, at least for the future, without incriminating itself. Such a proposal does not have to, and should not, provide carte blanche immunity for past actions but must enable publication and discussion of existing and future research. In this era of new-openness, the time may be ripe for the establishment of the tobacco-equivalent of the 'Justice and Truth' Commission employed in South Africa.
Nicotine regulation
To consider regulating nicotine means considering addiction. Benowitz and Henningfield [63] have proposed a gradual diminution in the weight of nicotine permitted in the actual cigarette. The idea has the merit of simplicity and practicability and is analogous to limiting the lead in petrol. If watched over by a competent regulatory agency, it would constitute a practical ongoing experiment which (duly monitored) should in due course reveal whether a non addictive, or less addictive, cigarette can be manufactured, whether it is saleable, and how customers react to it, not merely in terms of sales, but in patterns of use. This is not prohibition by stealth, it is a reasonable approach to making the cigarette less addictive.
The alternative approach, which might be to allow nicotine content to be unregulated so that the smoker is nicotine satisfied, rather than encouraged to suck harder and thereby inhale more carcinogens, is not a long-term solution to the problem of tobacco addiction.
There are three important points. The first point is simple. The index of nicotine delivery by the cigarette ought not to be the amount yielded to a machine running under one set of fixed conditions. Ideally, it ought to be a better reflection of what goes into the arterial blood of the smoker and will surely involve a series of tests conducted under a range of smoking conditions. Failing this a simpler and more practical index could be the actual weight per cigarette [63] . In addition it is necessary to reduce nicotine bioavailability so control of pH needs to be considered. Since some additives both facilitate nicotine bioavailability and themselves lead, when burnt, to carcinogen formation [64] , they need to be either abolished or subject to the same safety testing (in burnt and unburnt form) as nicotine replacement products are.
The second point is difficult. How to deal with compensatory smoking? This phenomenon has been known since the early work of Russell in the seventies. The tobacco industry has discovered a way to deal with this -delude the smoker into thinking the amount printed on the packet means something (light?) and make the nicotine more bioavailable by a variety of clever engineering techniques [64] . The knowledge that reducing nicotine to low levels drives deeper inhalation is the justification for the experimental approach proposed.
The solution to the controversy surrounding the effects of addiction and compensation has to be an ongoing epidemiological analysis of smoker behaviour in relation to nicotine content, as the nicotine content of cigarettes is progressively reduced en masse. Only in such a way can we develop a clear long term approach to the reduction of tobacco addiction. The fact that this is a population based, experimental approach should not be surprising. No ethical alternative is possible as the present cigarette is too dangerous to be allowed to remain on the market unchanged. Nearly all the important data we already have come from analysis of a massive (uncontrolled) human experiment, conducted, initially unwittingly, by an industry. Mass weaning of populations will not occur, on present experience, with the present cigarette. It may be, and probably is, possible. It will not happen while the tobacco industry is responsible for deciding what will be delivered by the cigarette. Neither will it happen unless there is a co-ordinated legislative program, preferably global, aimed at the progressive reduction of the addictive (and carcinogenic) properties of cigarettes.
The third point arises here. There is a strong case for regulating all forms of Nicotine, both nicotine coming from tobacco smoking ('dirty') and that from nonsmoking sources ('clean'). The pharmaceutical industry is experienced in collaborative regulation, but the tobacco industry is not. However, the drug needs to be considered at a societal level. So regulation of nicotine in cigarettes needs to be considered together with the existing regulation of alternative nicotine delivery systems, and by the same agency. While cigarette regulation needs to progressively tighten, the regulation of 'clean' nicotine could usefully be substantially loosened. The time is right to consider whether more efficiently absorbed forms of clean nicotine are needed and should be allowed to compete freely with tobacco derived nicotine.
The issues canvassed here are topical. There is now an opportunity to assert regulation over cigarettes in Europe, and indirectly to influence what happens elsewhere. While the concept of the Global Cigarette [65] in terms of maximum allowable limits of 12 mgms tar and 1 mgm nicotine has immediate validity for the developing countries where historical yields have been extremely high, a more sophisticated system is needed for developed, and eventually all, countries and this needs to become global as it evolves. With the global industry under pressure and the power to regulate incipient, Public Health Authorities and Governments which let slip the present opportunity to inhibit the epidemic will be judged harshly by history.
What can the oncological community do today?
Oncologists see daily the unforeseen consequences of cigarette smoking in their clinical practice. They are in a strong position to have an influential role in Tobacco Control although, surprisingly, they have never as a group exerted this potential.
It is important that oncologists set an example: it defies logic that oncologists continue to smoke knowing what they know, and see, about the long-term adverse effects of cigarettes. Oncological meetings should be completely non-smoking, smoking cessation advice and education should be available at these meetings and through learned societies, and oncologists should be trained in the methods of smoking cessation. However, smoking cessation is difficult and special efforts should be aimed at this professional group to increase the number of smokers who want to stop smoking and increase the probability that a quit attempt will be successful.
Oncologists have the potential to be a large and important group of activists. Currently there is a new Tobacco Directive being discussed in the European Parliament which proposes, among others, to further reduce tar ceilings and to introduce ceilings on nicotine and carbon monoxide; to obtain disclosure of the type and nature of tobacco additives to cigarettes; and to eliminate the use of adjectives such as 'low', 'mild', and 'ultra mild' which could be construed by the general public as implying a safer product. This Directive deserves the active support of European oncologists who should leave their elected representatives in no doubt about the importance and value of such legislation to public health.
